Similar articles

• Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis.

  Gertz MA, Brown ML, Hauser MF, Kyle RA. Gertz MA, et al. Arch Intern Med. 1987 Jun;147(6):1039-44. Arch Intern Med. 1987. PMID: 3036031
• Technetium 99m-pyrophosphate scintigraphy in amyloid cardiomyopathy.

  Ptacin MJ, Bamrah V, Duthie E. Ptacin MJ, et al. Wis Med J. 1985 Mar;84(3):25-7. Wis Med J. 1985. PMID: 2986368 No abstract available.
• [Cardiac amyloidosis].

  Jantunen E, Collan Y, Halinen MO, Kosma VM. Jantunen E, et al. Duodecim. 1987;103(4):192-8. Duodecim. 1987. PMID: 3038501 Review. Finnish. No abstract available.
• [Negativity of myocardial scintigraphy with technetium-pyrophosphate in a case of primary cardiac amyloidosis].

  Volpi A, Cavalli A, Maggioni AP, Inglese E, Rovelli GE, Neri R, Salvi A. Volpi A, et al. G Ital Cardiol. 1985 Sep;15(9):925-9. G Ital Cardiol. 1985. PMID: 3002892 Italian.
• Radiopharmaceutical supply disruptions and the use of ^99mTc-hydroxymethylene diphosphonate as an alternative to ^99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement.

  Miller EJ, Campisi R, Shah NR, McMahon S, Cuddy S, Gallegos-Kattan C, Maurer MS, Damy T, Slart RHJA, Bhatia K, Einstein AJ. Miller EJ, et al. J Nucl Cardiol. 2022 Oct;29(5):2748-2760. doi: 10.1007/s12350-022-03059-5. Epub 2022 Jul 15. J Nucl Cardiol. 2022. PMID: 35838892 Free PMC article. Review. No abstract available.